Phase I/II trial of high affinity natural killer cells (haNK) in combination with ganitumab for the treatment of Ewing's sarcoma

Trial Profile

Phase I/II trial of high affinity natural killer cells (haNK) in combination with ganitumab for the treatment of Ewing's sarcoma

Planning
Phase of Trial: Phase I/II

Latest Information Update: 26 May 2016

At a glance

  • Drugs Ganitumab (Primary) ; Natural killer cell therapy (Primary)
  • Indications Ewing's sarcoma
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 26 May 2016 New trial record
    • 17 May 2016 This trial is expected to initiate in the second half of 2016, according to a NantKwest media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top